​

EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EYPT Stock Forecast

EyePoint Pharmaceuticals (EYPT) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $11.21, with a high of $40.00 and a low of $0.50. This represents a 2506.98% increase from the last price of $0.43.

- $8 $16 $24 $32 $40 High: $40 Avg: $11.21 Low: $0.5 Last Closed Price: $0.43

EYPT Stock Rating

EyePoint Pharmaceuticals stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (55.00%), 8 Hold (40.00%), 1 Sell (5.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 1 8 11 Strong Sell Sell Hold Buy Strong Buy

EYPT Price Target Upside V Benchmarks

TypeNameUpside
StockEyePoint Pharmaceuticals2506.98%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3913
Avg Price Target$0.83$10.06$18.35
Last Closing Price$0.43$0.43$0.43
Upside/Downside93.02%2239.53%4167.44%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26166--13
Sep, 26175--13
Aug, 26311---14
Jul, 2639---12
Jun, 2639---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 20, 2026Lisa WalterRBC Capital$1.00$0.44127.27%132.56%
Oct 20, 2026Graig SuvannavejhMizuho Securities$0.50$0.4413.64%16.28%
Oct 19, 2026Faisal KhurshidJefferies$1.00$0.42138.10%132.56%
Sep 02, 2026China Renaissance Securities (US) Inc.$4.00$4.58-12.66%830.23%
Aug 18, 2026Chardan Capital$5.00$5.31-5.84%1062.79%
Aug 18, 2026RBC Capital$5.00$4.872.67%1062.79%
Aug 17, 2026Jefferies$8.00$4.6173.54%1760.47%
Aug 06, 2026H.C. Wainwright$27.00$12.25120.41%6179.07%
Jul 29, 2026Graig SuvannavejhMizuho Securities$39.00$11.96226.09%8969.77%
Jul 15, 2026Annabel SamimyStifel Nicolaus$40.00$13.85188.81%9202.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 20, 2026LaidlawBuyHolddowngrade
Oct 20, 2026RBC CapitalSector PerformSector Performhold
Oct 19, 2026GuggenheimBuyNeutraldowngrade
Oct 19, 2026JefferiesBuyHolddowngrade
Oct 19, 2026CitigroupBuyBuyhold
Sep 02, 2026Cowen & Co.ReduceHolddowngrade
Sep 02, 2026Cowen & Co.Reducedowngrade
Aug 18, 2026H.C. WainwrightBuyNeutraldowngrade
Aug 18, 2026RBC CapitalOutperformSector Performdowngrade
Aug 17, 2026LaidlawBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.03$-2.74$-1.82$-2.32$-3.17---
Avg Forecast$-1.95$-2.19$-1.94$-2.17$-2.51$-2.82$-2.42$0.11
High Forecast$-0.86$-1.18$-1.80$-1.86$-2.05$-2.26$-1.37$0.22
Low Forecast$-2.94$-3.48$-2.16$-2.31$-3.04$-3.27$-3.45$0.01
Surprise %4.10%25.11%-6.19%6.91%26.29%---

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$36.94M$41.40M$46.02M$43.27M$31.37M---
Avg Forecast$35.19M$41.28M$40.74M$42.56M$17.58M$12.48M$58.91M$310.06M
High Forecast$48.88M$60.17M$45.92M$53.22M$31.73M$12.48M$60.44M$559.56M
Low Forecast$20.04M$26.63M$32.38M$37.34M$5.18M$12.48M$57.38M$91.30M
Surprise %4.97%0.31%12.96%1.68%78.45%---

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-58.42M$-102.25M$-70.80M$-130.87M$-231.96M---
Avg Forecast$-76.02M$-61.30M$-70.80M$-80.95M$-99.07M$-107.54M$-93.87M$4.12M
High Forecast$-33.47M$-49.04M$-56.64M$-72.22M$-79.87M$-88.02M$-53.36M$8.43M
Low Forecast$-114.47M$-73.56M$-84.95M$-89.68M$-118.26M$-127.06M$-134.38M$341.29K
Surprise %-23.15%66.81%-61.67%134.15%---

EYPT Forecast FAQ

Is EyePoint Pharmaceuticals stock a buy?

EyePoint Pharmaceuticals stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that EyePoint Pharmaceuticals is a favorable investment for most analysts.

What is EyePoint Pharmaceuticals's price target?

EyePoint Pharmaceuticals's price target, set by 20 Wall Street analysts, averages $11.21 over the next 12 months. The price target range spans from $0.5 at the low end to $40 at the high end, suggesting a potential 2506.98% change from the previous closing price of $0.43.

How does EyePoint Pharmaceuticals stock forecast compare to its benchmarks?

EyePoint Pharmaceuticals's stock forecast shows a 2506.98% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for EyePoint Pharmaceuticals over the past three months?

  • October 2026: 7.69% Strong Buy, 46.15% Buy, 46.15% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 7.69% Strong Buy, 53.85% Buy, 38.46% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 21.43% Strong Buy, 78.57% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is EyePoint Pharmaceuticals’s EPS forecast?

EyePoint Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.82, marking a -11.04% decrease from the reported $-3.17 in 2025. Estimates for the following years are $-2.42 in 2027, and $0.11 in 2028.

What is EyePoint Pharmaceuticals’s revenue forecast?

EyePoint Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $12.48M, reflecting a -60.21% decrease from the reported $31.37M in 2025. The forecast for 2027 is $58.91M, and $310.06M for 2028.

What is EyePoint Pharmaceuticals’s net income forecast?

EyePoint Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-108M, representing a -53.64% decrease from the reported $-232M in 2025. Projections indicate $-93.87M in 2027, and $4.12M in 2028.